Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies
Donald Lynch(University of Cincinnati Medical Center), Benjamin E. Tourdot(Cincinnati Children's Hospital Medical Center), Colin F. Greineder(Translational Therapeutics (United States)), Boya Zhang(BioSurfaces (United States)), Emily N. Stringham(Cincinnati Children's Hospital Medical Center), Ginette Balbin-Cuesta(University of Michigan), Joseph S. Palumbo(Cincinnati Children's Hospital Medical Center), Brian R. Curtis(Versiti Blood Center of Wisconsin)
Cited by 9
Related Papers
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
|The Lancet Haematology|2019|329
Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice
|Blood|2012|305
Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race
|Blood|2014|132
ENTPD-1 disrupts inflammasome IL-1β–driven venous thrombosis
|Journal of Clinical Investigation|2019|116
First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis
|Arteriosclerosis Thrombosis and Vascular Biology|2017|112